Emerging Uloric Litigation
Uloric made by Takeda Pharmaceuticals gained FDA approval subsequent to New Drug Application (NDA: 021856) in February 2009.
Takeda Pharmaceuticals is facing multiple Qui Tam lawsuits filed by a former safety consultant for the company. These suits that the company withheld information about dangerous side effects related to Uloric, including kidney problems, liver damage, bone marrow failure, drug interactions and more.
Gout, a type of arthritis that occurs when uric acid crystals build up in the joints. Gout has been found to be more common in men than in women Gout is believed affects about 8.3 million people, or 4% of the U.S. population.
Uloric was the first new drug approved to treat Gout in 40 years. Unfortunately, this new treatment which promised relief for those who suffer from Gout, appears to have numerous significant and potentially life threatening side effects that Takeda never warned the public about.
Learn More About the Emerging Uloric Litigation
The emerging Uloric Litigation will be used as a case study in the May 18-21, 2018 Mass Tort Nexus “Four Days to Mass Tort Success Course” To register for the May Couse, contact Jenny Levine at email@example.com or call (954) 520-4494.
For information on the class and to enroll, use this link-“Enroll Here To Attend “Four Days to Mass Tort Success”
Course attendees will receive the benefit of a step by step analysis of the emerging Uloric
Litigation, using these primary metrics:
Some of the top mass tort trial lawyers in the country have endorsed the Mass Tort Nexus Immersion Course, including CNN Legal Analyst Mark O’Mara>
The Mass Tort Nexus Classes on Emerging Litigation and Ongoing Mass Torts are considered the premier source in the country to learn about the fundamentals of mass torts and how to enhance your firm practice, increase revenues and manage the related business operations effectively. Don’t wait for the next class or next year, enroll today and learn what others already have, Mass Torts are where your firm can and will grow its practice.